Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
177 hedge funds and large institutions have $3.36B invested in Mirati Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 68 increasing their positions, 57 reducing their positions, and 24 closing their positions.
39% more call options, than puts
Call options by funds: $221M | Put options by funds: $159M
21% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 24
19% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 57
3% more funds holding
Funds holding: 172 → 177 (+5)
25% less capital invested
Capital invested by funds: $4.48B → $3.36B (-$1.12B)
54% less funds holding in top 10
Funds holding in top 10: 13 → 6 (-7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$50.2M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$46.9M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$40.5M |
| 4 |
PA
Perceptive Advisors
New York
|
+$38.9M |
| 5 |
RI
RTW Investments
New York
|
+$31.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$113M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$69.4M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$65.2M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$51.9M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$24M |
MRTX Hedge Fund Activity: Q3 2019 in Review
177 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q3 2019, worth a combined $3.36B — down 25% from $4.48B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new MRTX positions and 24 closed out — a net gain of 5 holders — while 68 added to existing stakes and 57 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $50.2M. The largest seller was Baker Bros. Advisors, cutting an estimated $113M.
- 177 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q3 2019, up from 172 in Q2 2019.
- Funds reported $3.36B of Mirati Therapeutics, Inc. Common Stock stock for Q3 2019, down 25% quarter-over-quarter.
- 29 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q3 2019 and 24 closed out, a net change of +5 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q3 2019 was OrbiMed, an estimated $50.2M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q3 2019 was Baker Bros. Advisors, an estimated $113M sold.
Based on aggregated 13F filings for Q3 2019.